Notable Labs

Notable Labs Current Assets

The Current Assets of Notable Labs (NTBLQ) as of Nov 10, 2026 is 15.47 M USD. In the previous year, Current Assets was 22.04 M USD — a change of -29.81% (lower).

Current Assets

15.47 MUSD

YoY

-29.81%

Last updated:

Current Assets of Notable Labs is 2023 15.47 M USD. Current Assets of Notable Labs was 2022 22.04 M USD. It decreases by -29.81% lower compared to the previous year.

The Notable Labs Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2016
46.57 M USD
Jan 1, 2017
58.46 M USD
Jan 1, 2018
51.71 M USD
Jan 1, 2019
37.78 M USD
Jan 1, 2020
31.99 M USD
Jan 1, 2021
54.86 M USD
Jan 1, 2022
22.04 M USD
Jan 1, 2023
15.47 M USD
The Notable Labs Current Assets history
YEARCurrent AssetsYoY
15.47 MUSD-29.81%
22.04 MUSD-59.83%
54.86 MUSD+71.49%
31.99 MUSD-15.33%
37.78 MUSD-26.94%
51.71 MUSD-11.55%
58.46 MUSD+25.53%
46.57 MUSD+20.65%
38.60 MUSD+2.25%
37.75 MUSD+231.72%
11.38 MUSD-22.16%
14.62 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Current Assets of Notable Labs is 15.47 M USD in 2023.

Current Assets of Notable Labs changed from 22.04 M USD to 15.47 M USD, representing a -29.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Notable Labs

All Key Metrics — Notable Labs